This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Oct 11;372(9646):1298; author reply 1298-9.

doi: 10.1016/S0140-6736(08)61543-3.

Effect of aciclovir on HIV-1 acquisition in HSV-2-positive patients

PMID: 18929897
DOI: 10.1016/S0140-6736(08)61543-3

Comment

Effect of aciclovir on HIV-1 acquisition in HSV-2-positive patients

C P Hudson. Lancet. 2008.

. 2008 Oct 11;372(9646):1298; author reply 1298-9.

doi: 10.1016/S0140-6736(08)61543-3.

Author

PMID: 18929897
DOI: 10.1016/S0140-6736(08)61543-3

No abstract available

PubMed Disclaimer

Comment on

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.
Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L; HPTN 039 Protocol Team. Celum C, et al. Lancet. 2008 Jun 21;371(9630):2109-19. doi: 10.1016/S0140-6736(08)60920-4. Lancet. 2008. PMID: 18572080 Free PMC article. Clinical Trial.

Similar articles

Treating HIV infection with drugs for HSV-2 infection?
Buvé A, Lynen L. Buvé A, et al. Lancet. 2010 Mar 6;375(9717):782-4. doi: 10.1016/S0140-6736(10)60097-9. Epub 2010 Feb 12. Lancet. 2010. PMID: 20153889 No abstract available.
The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G. Vickerman P, et al. Sex Transm Dis. 2011 May;38(5):401-9. doi: 10.1097/OLQ.0b013e31820b8bc8. Sex Transm Dis. 2011. PMID: 21317689 Clinical Trial.
Treatment of HIV infection with drugs for HSV-2 infection.
Huttner A, Calmy A. Huttner A, et al. Lancet. 2010 Jul 10;376(9735):88; author reply 88. doi: 10.1016/S0140-6736(10)61069-0. Lancet. 2010. PMID: 20621229 No abstract available.
Recent developments in the management of herpes simplex virus infection in HIV-infected persons.
Bartlett JG. Bartlett JG. Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S237-9. doi: 10.1086/422360. Clin Infect Dis. 2004. PMID: 15494894 Review. No abstract available.
Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
Celum CL, Robinson NJ, Cohen MS. Celum CL, et al. J Infect Dis. 2005 Feb 1;191 Suppl 1:S107-14. doi: 10.1086/425272. J Infect Dis. 2005. PMID: 15627220 Review.

See all similar articles

Cited by

A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
Vanpouille C, Lisco A, Derudas M, Saba E, Grivel JC, Brichacek B, Scrimieri F, Schinazi R, Schols D, McGuigan C, Balzarini J, Margolis L. Vanpouille C, et al. J Infect Dis. 2010 Feb 15;201(4):635-43. doi: 10.1086/650343. J Infect Dis. 2010. PMID: 20085496 Free PMC article.
A missed point in deciphering the viral synergy between herpes simplex virus and HIV.
Lisco A, Vanpouille C, Margolis L. Lisco A, et al. Lancet Infect Dis. 2009 Sep;9(9):522-3. doi: 10.1016/S1473-3099(09)70209-9. Lancet Infect Dis. 2009. PMID: 19695487 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information